2. Do not fall in love with a stock.
Combining a biotech bubble with emotional trading is a recipe for disaster. A recent example is Sarepta Therapeutics (SRPT - Get Report), which popped to over $45 on very compelling muscular dystrophy data and an incredibly heartwarming story of a drug that helps seriously ill kids. After spiking over 200% ($15 to $45) the stock has corrected to the $30 level. Traders who did not check their emotions at the door and bought into the hype of the stock are now down 30% or more. There is nothing wrong with taking profits and moving on to the next trade. Traders should trade, not invest.
3. Watch closely for signs of a market shift.
Biotech mania in full swing doesn't necessarily mean that a correction is imminent. The bullish trend can continue. Trade with strategies that work for you, but when the market starts to shift, be ready to shift with it. Monitor the price action of upcoming biotech run-up stocks and overall trader sentiment. While I don't believe in over-analyzing macro trends, you need to be aware of coming market-moving events like the U.S. presidential elections and the risk that our economy goes over the so-called "fiscal cliff."4. Be prepared to quickly change your trading strategy. If the market shifts, a biotech trader needs to be prepared to make quick adjustments to stay profitable. In bear markets, shorting the spike on any piece of positive news was very profitable, as people were quick to take profits and move on. If/when the biotech market shifts, I'm ready to make the following adjustments: Limit run-up trades to FDA approval decision and advisory panels. No NDA filings or clinical trials with solid fixed dates for data release. Hold off buying until closer to the catalyst. For example, instead of going long on a position 4-5 months before a PDUFA date, wait until 6-8 weeks prior. Aggressively short positive news on biotechs that have experienced a run-up. As a trader you need to be prepared and ready to trade in any market, bear or bull. Having a plan ready and staying aware of market conditions will allow you to maintain profitability while "shoeshine" traders are struggling. Messier has no positions in stocks mentioned in this column.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts